{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:03:50Z","timestamp":1793250230447,"version":"4.5.0"},"reference-count":174,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["PR9"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This article presents an overview of fundamental statistical principles of clinical trials of pain treatments. Statistical considerations relevant to phase 2 proof of concept and phase 3 confirmatory randomized trials investigating efficacy and safety are discussed, including (1) research design; (2) endpoints and analyses; (3) sample size determination and statistical power; (4) missing data and trial estimands; (5) data monitoring and interim analyses; and (6) interpretation of results. Although clinical trials of pharmacologic treatments are emphasized, the key issues raised by these trials are also directly applicable to clinical trials of other types of treatments, including biologics, devices, nonpharmacologic therapies (eg, physical therapy and cognitive-behavior therapy), and complementary and integrative health interventions.<\/jats:p>","DOI":"10.1097\/pr9.0000000000000863","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T21:44:05Z","timestamp":1611611045000},"page":"e863","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Essential statistical principles of clinical trials of pain treatments"],"prefix":"10.1097","volume":"6","author":[{"given":"Robert H.","family":"Dworkin","sequence":"first","affiliation":[{"name":"Departments of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, and Center for Health + Technology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics and the Biostatistics Center, George, Washington University, Washington DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Mbowe","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Departments of Biostatistics and Computational Biology and Neurology, and Center for Health + Technology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1]]},"reference":[{"key":"R1-20240807","article-title":"On reporting and interpreting statistical significance and p values in medical research","author":"Aguinis","year":"2019","journal-title":"BMJ Evid Based Med"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/bmj.281.6249.1182","article-title":"Statistics and ethics in medical research: misuse of statistics is unethical","volume":"281","author":"Altman","year":"1980","journal-title":"BMJ"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/bmj.281.6251.1336","article-title":"Statistics and ethics in medical research, III: how large a sample?","volume":"281","author":"Altman","year":"1980","journal-title":"BMJ"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/bmj.282.6257.44","article-title":"Statistics and ethics in medical research, VIII: improving the quality of statistics in medical journals","volume":"282","author":"Altman","year":"1981","journal-title":"BMJ"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0197-2456(03)00107-7","article-title":"An international multicenter protocol to assess the single and combined benefits of antiemetic interventions in a controlled clinical trial of a 2x2x2x2x2x2 factorial design (IMPACT)","volume":"24","author":"Apfel","year":"2003","journal-title":"Control Clin Trials"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa032196","article-title":"A factorial trial of six interventions for the prevention of postoperative nausea and vomiting","volume":"350","author":"Apfel","year":"2004","journal-title":"N Eng J Med"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/19466315.2019.1677494","article-title":"Interim monitoring for futility in clinical trials with two co-primary endpoints using prediction","volume":"12","author":"Asakura","year":"2020","journal-title":"Stat Biopharm Res"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10543406.2013.859148","article-title":"A multiple-imputation-based approach to sensitivity analyses and effectiveness assessments in longitudinal clinical trials","volume":"24","author":"Ayele","year":"2014","journal-title":"J Biopharm Stat"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/sim.6472","article-title":"Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls","volume":"35","author":"Bauer","year":"2016","journal-title":"Stat Med"},{"key":"R10-20240807","first-page":"400","article-title":"Looking for important change\/differences in studies of responsiveness","volume":"28","author":"Beaton","year":"2001","journal-title":"J Rheumatol"},{"key":"R11-20240807","article-title":"It's not the p-values' fault","author":"Benjamini","year":"2016","journal-title":"Am Stat Online"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"N adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/rheumatology\/kel296","article-title":"Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies","volume":"46","author":"Bingham","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.2010.651","article-title":"Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes","volume":"303","author":"Boutron","year":"2010","journal-title":"JAMA"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/sim.4780080204","article-title":"Factorial designs in clinical trials: the effects of non-compliance and subadditivity","volume":"8","author":"Brittain","year":"1989","journal-title":"Stat Med"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/sim.4780090112","article-title":"Factorial and reciprocal control designs","volume":"9","author":"Byar","year":"1990","journal-title":"Stat Med"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/19466315.2019.1629997","article-title":"Estimands in a chronic pain trial: challenges and opportunities","volume":"12","author":"Callegari","year":"2020","journal-title":"Stat Biopharm Res"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/10543406.2013.834911","article-title":"Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation","volume":"23","author":"Carpenter","year":"2013","journal-title":"J Biopharm Stat"},{"key":"R23-20240807","doi-asserted-by":"crossref","first-page":"b1732","DOI":"10.1136\/bmj.b1732","article-title":"Reporting of sample size calculation in randomized controlled trials: review","volume":"338","author":"Charles","year":"2009","journal-title":"BMJ"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/009286150804200304","article-title":"Measures for conducting comparative benefit:risk assessment","volume":"42","author":"Chuang-Stein","year":"2008","journal-title":"Drug Inf J"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1740774512461859","article-title":"Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop","volume":"9","author":"Coffey","year":"2012","journal-title":"Clin Trials"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"j5748","DOI":"10.1136\/bmj.j5748","article-title":"Statistical methods to compare functional outcomes in randomized controlled trials with high mortality","volume":"360","author":"Colantuoni","year":"2018","journal-title":"BMJ"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/1740774514521907","article-title":"Use of methods for specifying the target difference in randomised controlled trial sample size calculations: two surveys of trialists' practice","volume":"11","author":"Cook","year":"2014","journal-title":"Clin Trials"},{"key":"R29-20240807","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13063-014-0526-8","article-title":"Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers","volume":"16","author":"Cook","year":"2015","journal-title":"Trials"},{"key":"R30-20240807","doi-asserted-by":"crossref","first-page":"k3750","DOI":"10.1136\/bmj.k3750","article-title":"DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomized controlled trial","volume":"363","author":"Cook","year":"2018","journal-title":"BMJ"},{"key":"R32-20240807","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/(SICI)1097-0258(20000330)19:6<763::AID-SIM517>3.0.CO;2-8","article-title":"Controlling alpha in a clinical trial: the case for secondary endpoints","volume":"19","author":"D'Agostino","year":"2000","journal-title":"Stat Med"},{"key":"R33-20240807","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"PAIN"},{"key":"R34-20240807","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/sim.5405","article-title":"Current development in clinical trials: issues old and new","volume":"31","author":"DeMets","year":"2012","journal-title":"Stat Med"},{"key":"R35-20240807","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00002060-199002000-00003","article-title":"Can trials of physical treatments be blinded?: the example of transcutaneous electrical nerve stimulation for chronic pain","volume":"69","author":"Deyo","year":"1990","journal-title":"Am J Phys Med Rehabil"},{"key":"R36-20240807","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1056\/NEJMra1709701","article-title":"Multiplicity considerations in clinical trials","volume":"378","author":"Dmitrienko","year":"2018","journal-title":"N Engl J Med"},{"key":"R37-20240807","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2015.10.019","article-title":"Deficiencies in reporting of statistical methodology in recent randomized trials of non-pharmacologic pain treatments: ACTTION systematic review","volume":"72","author":"Dworkin","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"R38-20240807","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/j.pain.0000000000000771","article-title":"Phenotypes and treatment response: it's difficult to make predictions, especially about the future","volume":"158","author":"Dworkin","year":"2017","journal-title":"PAIN"},{"key":"R39-20240807","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"PAIN"},{"issue":"suppl","key":"R40-20240807","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.pain.2010.11.008","article-title":"Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION","volume":"152","author":"Dworkin","year":"2011","journal-title":"PAIN"},{"key":"R41-20240807","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","article-title":"Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations","volume":"146","author":"Dworkin","year":"2009","journal-title":"PAIN"},{"key":"R42-20240807","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pain.2010.02.018","article-title":"Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations","volume":"149","author":"Dworkin","year":"2010","journal-title":"PAIN"},{"key":"R43-20240807","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.pain.2012.03.003","article-title":"Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations","volume":"153","author":"Dworkin","year":"2012","journal-title":"PAIN"},{"key":"R44-20240807","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"R45-20240807","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/j.pain.0000000000000602","article-title":"Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations","volume":"157","author":"Edwards","year":"2016","journal-title":"PAIN"},{"key":"R46-20240807","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(97)02290-3","article-title":"Why \"underpowered\" trials are not necessarily unethical","volume":"350","author":"Edwards","year":"1997","journal-title":"Lancet"},{"key":"R49-20240807","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/biomet\/77.4.875","article-title":"Parameter estimation following group sequential hypothesis testing","volume":"77","author":"Emerson","year":"1990","journal-title":"Biometrika"},{"key":"R52-20240807","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pctr.0020018","article-title":"When and how can endpoints be changed after initiation of a randomized clinical trial?","volume":"2","author":"Evans","year":"2007","journal-title":"PLoS Clin Trials"},{"key":"R53-20240807","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/M19-1491","article-title":"Presenting risks and benefits: helping the data monitoring committee do its job","volume":"172","author":"Evans","year":"2020","journal-title":"Ann Intern Med"},{"key":"R54-20240807","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","article-title":"Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation","volume":"8","author":"Evans","year":"2016","journal-title":"Stat Biopharm Res"},{"key":"R55-20240807","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/009286150704100606","article-title":"Data monitoring in clinical trials using prediction","volume":"41","author":"Evans","year":"2007","journal-title":"Drug Inf J"},{"key":"R56-20240807","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R58-20240807","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpainsymman.2005.08.018","article-title":"Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable","volume":"31","author":"Farrar","year":"2006","journal-title":"J Pain Symptom Manage"},{"key":"R59-20240807","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"PAIN"},{"key":"R60-20240807","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pst.331","article-title":"Consequences of dichotomization","volume":"8","author":"Fedorov","year":"2009","journal-title":"Pharm Stat"},{"key":"R61-20240807","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jclinepi.2013.02.018","article-title":"The smallest worthwhile effect of nonsteroidal anti-inflammatory drugs and physiotherapy for chronic low back pain: a benefit-harm trade-off study","volume":"66","author":"Ferreira","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"R62-20240807","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1097\/j.pain.0000000000001340","article-title":"Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy","volume":"159","author":"Finnerup","year":"2018","journal-title":"PAIN"},{"key":"R64-20240807","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/sim.2855","article-title":"Current issues in non-inferiority trials","volume":"27","author":"Fleming","year":"2008","journal-title":"Stat Med"},{"key":"R65-20240807","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJMe0807372","article-title":"Identifying and addressing safety signals in clinical trials","volume":"359","author":"Fleming","year":"2008","journal-title":"N Engl J Med"},{"key":"R67-20240807","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/AOG.0b013e3181e9e0ab","article-title":"Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial","volume":"116","author":"Foster","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R68-20240807","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.289.19.2554","article-title":"Composite outcomes in randomized trials: greater precision but with greater uncertainty?","volume":"289","author":"Freemantle","year":"2003","journal-title":"JAMA"},{"key":"R69-20240807","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jnci\/djp477","article-title":"Randomized clinical trials with biomarkers: design issues","volume":"102","author":"Freidlin","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"R70-20240807","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/bimj.200510238","article-title":"Sample size recalculation in internal pilot study designs: a review","volume":"48","author":"Friede","year":"2006","journal-title":"Biom J"},{"key":"R71-20240807","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1155\/2011\/465281","article-title":"A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain","volume":"16","author":"Furlan","year":"2011","journal-title":"Pain Res Manage"},{"key":"R72-20240807","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1191\/1740774506cn134oa","article-title":"The continual reassessment method for dose-finding studies: a tutorial","volume":"3","author":"Garrett-Mayer","year":"2006","journal-title":"Clin Trials"},{"key":"R73-20240807","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/009286150904300503","article-title":"Good practices for adaptive clinical trials in pharmaceutical product development","volume":"43","author":"Gaydos","year":"2009","journal-title":"Drug Inf J"},{"key":"R75-20240807","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/j.pain.0000000000000191","article-title":"Research designs considerations for chronic pain prevention clinical trials: IMMPACT recommendations","volume":"156","author":"Gewandter","year":"2015","journal-title":"PAIN"},{"key":"R76-20240807","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.pain.2014.05.025","article-title":"Research design considerations for proof-of-concept chronic pain clinical trials: IMMPACT recommendations","volume":"155","author":"Gewandter","year":"2014","journal-title":"PAIN"},{"key":"R77-20240807","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1097\/PR9.0000000000000621","article-title":"Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT","volume":"4","author":"Gewandter","year":"2019","journal-title":"Pain Rep"},{"key":"R78-20240807","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.12.018","article-title":"Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review and recommendations","volume":"83","author":"Gewandter","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"R79-20240807","doi-asserted-by":"crossref","first-page":"e017288","DOI":"10.1136\/bmjopen-2017-017288","article-title":"Interpretation of CIs in clinical trials with non-significant results: systematic review and recommendations","volume":"7","author":"Gewandter","year":"2017","journal-title":"BMJ Open"},{"key":"R80-20240807","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/j.pain.0000000000001504","article-title":"Navigating trials of personalized pain treatments: we\u2019re going to need a bigger boat","volume":"160","author":"Gewandter","year":"2019","journal-title":"PAIN"},{"key":"R81-20240807","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpain.2014.10.003","article-title":"Data interpretation in analgesic clinical trials with statistically nonsignificant primary analyses: an ACTTION systematic review","volume":"16","author":"Gewandter","year":"2015","journal-title":"J Pain"},{"key":"R82-20240807","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.pain.2013.11.009","article-title":"Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations","volume":"155","author":"Gewandter","year":"2014","journal-title":"PAIN"},{"key":"R83-20240807","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/YIC.0b013e32834f504f","article-title":"Obtained effect size as a function of sample size in approved antidepressants: a real-world illustration in support of better trial design","volume":"27","author":"Gibertini","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"R84-20240807","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/bmj.311.7016.1356","article-title":"An evidence based approach to individualising treatment","volume":"311","author":"Glasziou","year":"1995","journal-title":"BMJ"},{"key":"R85-20240807","first-page":"561","article-title":"Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles","volume":"20","author":"Goldsmith","year":"1993","journal-title":"J Rheumatol"},{"key":"R86-20240807","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-121-3-199408010-00008","article-title":"The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results","volume":"121","author":"Goodman","year":"1994","journal-title":"Ann Intern Med"},{"key":"R87-20240807","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/bmj.316.7132.690","article-title":"Interpreting treatment effects in randomised trials","volume":"316","author":"Guyatt","year":"1998","journal-title":"BMJ"},{"key":"R88-20240807","doi-asserted-by":"crossref","first-page":"d3340","DOI":"10.1136\/bmj.d3340","article-title":"Interpreting and reporting clinical trials with results of borderline significance","volume":"343","author":"Hackshaw","year":"2011","journal-title":"BMJ"},{"key":"R89-20240807","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.288.3.358","article-title":"The continuing unethical conduct of underpowered clinical trials","volume":"288","author":"Halpern","year":"2002","journal-title":"JAMA"},{"key":"R91-20240807","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/10543406.2017.1378668","article-title":"Design, data monitoring, and analysis of clinical trials with co-primary endpoints: a review","volume":"28","author":"Hamasaki","year":"2018","journal-title":"J Biopharm Stat"},{"key":"R92-20240807","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","article-title":"Repeated assessment of results in clinical trials of cancer treatment","volume":"44","author":"Haybittle","year":"1971","journal-title":"Br J Radiol"},{"key":"R93-20240807","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jclinepi.2003.09.014","article-title":"Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements","volume":"57","author":"Hern\u00e1ndez","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"R94-20240807","doi-asserted-by":"crossref","first-page":"e1001645","DOI":"10.1371\/journal.pmed.1001645","article-title":"Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) systematic review","volume":"11","author":"Hislop","year":"2014","journal-title":"PLoS Med"},{"key":"R95-20240807","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1198\/000313001300339897","article-title":"The abuse of power: the pervasive fallacy of power calculations for data analysis","volume":"55","author":"Hoenig","year":"2001","journal-title":"Am Stat"},{"key":"R96-20240807","doi-asserted-by":"crossref","first-page":"g4145","DOI":"10.1136\/bmj.g4145","article-title":"Impact of peer review on reports of randomised trials published in open peer review journals: retrospective before and after study","volume":"349","author":"Hopewell","year":"2014","journal-title":"BMJ"},{"key":"R97-20240807","doi-asserted-by":"crossref","first-page":"e1119","DOI":"10.1136\/bmj.e1119","article-title":"Observer bias in randomized clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors","volume":"344","author":"Hr\u00f3bjartsson","year":"2012","journal-title":"BMJ"},{"key":"R98-20240807","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.pain.2014.08.004","article-title":"Adverse event reporting in nonpharmacologic, noninterventional pain clinical trials: ACTTION systematic review","volume":"155","author":"Hunsinger","year":"2014","journal-title":"PAIN"},{"key":"R99-20240807","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/1467-985X.00175","article-title":"Number needed to treat: properties and problems","volume":"163","author":"Hutton","year":"2000","journal-title":"J R Stat Soc A"},{"key":"R101-20240807","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0140-6736(13)62227-8","article-title":"Increasing value and reducing waste in research design, conduct, and analysis","volume":"383","author":"Ioannidis","year":"2014","journal-title":"Lancet"},{"key":"R103-20240807","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/bmj.313.7048.36","article-title":"Trials to assess equivalence: the importance of rigorous methods","volume":"313","author":"Jones","year":"1996","journal-title":"BMJ"},{"key":"R105-20240807","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1745-6215-15-139","article-title":"The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies","volume":"15","author":"Kahan","year":"2014","journal-title":"Trials"},{"key":"R106-20240807","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cct.2012.02.013","article-title":"Early phase drug development for treatment of chronic pain: options for clinical trial and program design","volume":"33","author":"Kalliom\u00e4ki","year":"2012","journal-title":"Contemp Clin Trials"},{"key":"R107-20240807","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/AJP.0b013e3181b12dec","article-title":"Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology","volume":"25","author":"Katz","year":"2009","journal-title":"Clin J Pain"},{"key":"R110-20240807","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1176\/appi.ajp.2017.17091016","article-title":"The impact of underpowered studies on clinical trial results","volume":"175","author":"Khan","year":"2018","journal-title":"Am J Psychiatry"},{"key":"R111-20240807","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/wps.20421","article-title":"Has the rising placebo response impacted antidepressant clinical trial outcome?: data from the US Food and Drug Administration 1987-2013","volume":"16","author":"Khan","year":"2017","journal-title":"World Psychiatry"},{"key":"R112-20240807","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2307\/2531502","article-title":"Point estimation following group sequential tests","volume":"45","author":"Kim","year":"1989","journal-title":"Biometrics"},{"key":"R113-20240807","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10543406.2011.550112","article-title":"Missing data handling in chronic pain trials","volume":"21","author":"Kim","year":"2011","journal-title":"J Biopharm Stat"},{"key":"R114-20240807","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0895-4356(91)90208-Q","article-title":"The qualification period","volume":"44","author":"Knipschild","year":"1991","journal-title":"J Clin Epidemlol"},{"key":"R115-20240807","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1200\/JCO.2010.31.1423","article-title":"Outcome-adaptive randomization: is it useful?","volume":"29","author":"Korn","year":"2011","journal-title":"J Clin Oncol"},{"key":"R116-20240807","first-page":"217","article-title":"To increase power in randomized clinical trials without increasing sample size","volume":"27","author":"Kraemer","year":"1991","journal-title":"Psychopharmacol Bull"},{"key":"R117-20240807","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer","year":"2006","journal-title":"Biol Psychiatry"},{"key":"R118-20240807","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/archpsyc.63.5.484","article-title":"Caution regarding the use of pilot studies to guide power calculations for study proposals","volume":"63","author":"Kraemer","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R119-20240807","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1097\/00004583-200312000-00022","article-title":"Measures of clinical significance","volume":"42","author":"Kraemer","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R120-20240807","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/2336502","article-title":"Discrete sequential boundaries for clinical trials","volume":"70","author":"Lan","year":"1983","journal-title":"Biometrika"},{"key":"R121-20240807","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/sim.6840","article-title":"A regulatory perspective on missing data in the aftermath of the NRC report","volume":"35","author":"LaVange","year":"2016","journal-title":"Stat Med"},{"key":"R122-20240807","first-page":"3","article-title":"Is there an alternative to the randomized controlled trial?","volume":"27","author":"Leber","year":"1991","journal-title":"Psychopharmacol Bull"},{"key":"R123-20240807","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0197-2456(97)00118-9","article-title":"Threats to the validity of clinical trials employing enrichment strategies for sample selection","volume":"19","author":"Leber","year":"1998","journal-title":"Control Clin Trials"},{"key":"R124-20240807","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1198\/000313001317098149","article-title":"Some practical guidelines for effective sample size determination","volume":"55","author":"Lenth","year":"2001","journal-title":"Am Stat"},{"key":"R125-20240807","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archpsyc.1995.03950220077014","article-title":"More reliable outcome measures can reduce sample size requirements","volume":"52","author":"Leon","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"R126-20240807","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/pst.1791","article-title":"Disentangling estimands and the intention-to-treat principle","volume":"16","author":"Leuchs","year":"2017","journal-title":"Pharm Stat"},{"key":"R127-20240807","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1177\/2168479014567317","article-title":"Choosing appropriate estimands in clinical trials","volume":"49","author":"Leuchs","year":"2015","journal-title":"Ther Innov Regul Sci"},{"key":"R128-20240807","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1198\/sbr.2009.0041","article-title":"Predicted interval plots (PIPS): a graphical tool for data monitoring in clinical trials","volume":"1","author":"Li","year":"2009","journal-title":"Stat Biopharm Res"},{"key":"R129-20240807","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/pst.1765","article-title":"Choosing estimands in clinical trials with missing data","volume":"16","author":"Mallinckrodt","year":"2017","journal-title":"Pharm Stat"},{"key":"R130-20240807","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/009286150804200402","article-title":"Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials","volume":"42","author":"Mallinckrodt","year":"2008","journal-title":"Drug Inf J"},{"key":"R131-20240807","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pst.1536","article-title":"A structured approach to choosing estimands and estimators in longitudinal clinical trials","volume":"11","author":"Mallinckrodt","year":"2012","journal-title":"Pharm Stat"},{"key":"R132-20240807","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/sim.4780140204","article-title":"Small clinical trials: are they all bad?","volume":"14","author":"Matthews","year":"1995","journal-title":"Stat Med"},{"key":"R135-20240807","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jpain.2014.11.010","article-title":"Reporting of sample size calculations in analgesic clinical trials: ACTTION systematic review","volume":"16","author":"McKeown","year":"2015","journal-title":"J Pain"},{"key":"R136-20240807","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pain.2008.01.014","article-title":"Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain","volume":"135","author":"McQuay","year":"2008","journal-title":"PAIN"},{"key":"R137-20240807","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archpsyc.61.4.412","article-title":"Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial","volume":"61","author":"McRae","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"R138-20240807","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/pst.1817","article-title":"Missing data in clinical trials: control-based mean imputation and sensitivity analysis","volume":"16","author":"Mehrotra","year":"2017","journal-title":"Pharm Stat"},{"key":"R139-20240807","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bmj.326.7400.1171","article-title":"Evidence b(i)ased medicine\u2500selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications","volume":"326","author":"Melander","year":"2003","journal-title":"BMJ"},{"key":"R141-20240807","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/biostatistics\/kxh001","article-title":"Analyzing incomplete longitudinal clinical trial data","volume":"5","author":"Molenberghs","year":"2004","journal-title":"Biostatistics"},{"key":"R142-20240807","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/j.1532-2149.2013.00341.x","article-title":"Duloxetine use in chronic painful conditions: individual patient data responder analysis","volume":"18","author":"Moore","year":"2014","journal-title":"Eur J Pain"},{"key":"R143-20240807","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pain.2011.10.004","article-title":"Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses","volume":"153","author":"Moore","year":"2012","journal-title":"PAIN"},{"key":"R144-20240807","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/j.pain.0000000000000088","article-title":"Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting","volume":"156","author":"Moore","year":"2015","journal-title":"PAIN"},{"key":"R145-20240807","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/clpt.1987.26","article-title":"Blinding, unblinding, and the placebo effect: an analysis of patients' guesses of treatment assignment in a double-blind clinical trial","volume":"41","author":"Moscucci","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"R147-20240807","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"R148-20240807","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/art.24894","article-title":"The importance of allocation concealment and patient blinding in osteoarthritis trials: a meta-epidemiologic study","volume":"61","author":"Nuesch","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R149-20240807","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O'Brien","year":"1979","journal-title":"Biometrics"},{"key":"R150-20240807","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009286150704100105","article-title":"Multiple co-primary endpoints: medical and statistical solutions: a report from the multiple endpoints expert team of the Pharmaceutical Research and Manufacturers of America","volume":"41","author":"Offen","year":"2007","journal-title":"Drug Inf J"},{"key":"R152-20240807","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12916-016-0775-3","article-title":"Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain","volume":"15","author":"Olsen","year":"2017","journal-title":"BMC Med"},{"key":"R153-20240807","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jclinepi.2018.05.007","article-title":"Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies","volume":"101","author":"Olsen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"R154-20240807","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/009286150804200305","article-title":"A perspective on characterizing benefits and risks derived from clinical trials: can we do more?","volume":"42","author":"O'Neil","year":"2008","journal-title":"Drug Inf J"},{"key":"R155-20240807","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/009286150103500408","article-title":"Interim monitoring of group sequential trials using spending functions for the type I and type II error probabilities","volume":"35","author":"Pampallona","year":"2001","journal-title":"Drug Inf J"},{"key":"R156-20240807","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4088\/JCP.14r09297","article-title":"The nature of placebo response in clinical studies of major depressive disorder","volume":"76","author":"Papakostas","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"R157-20240807","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1097\/j.pain.0000000000001324","article-title":"Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysis","volume":"159","author":"Patel","year":"2018","journal-title":"PAIN"},{"key":"R158-20240807","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/009286150704100604","article-title":"A note on stratification in clinical trials","volume":"41","author":"Permutt","year":"2007","journal-title":"Drug Inf J"},{"key":"R159-20240807","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/sim.6841","article-title":"A taxonomy of estimands for regulatory clinical trials with discontinuations","volume":"35","author":"Permutt","year":"2016","journal-title":"Stat Med"},{"key":"R160-20240807","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pst.1768","article-title":"Trimmed means for symptom trials with dropouts","volume":"16","author":"Permutt","year":"2017","journal-title":"Pharm Stat"},{"key":"R161-20240807","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.1976.220","article-title":"Design and analysis of randomized clinical trials requiring prolonged observations of each patient, I: introduction and design","volume":"34","author":"Peto","year":"1976","journal-title":"Br J Cancer"},{"key":"R162-20240807","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/pst.1745","article-title":"Estimands: discussion points from the PSI estimands and sensitivity expert group","volume":"16","author":"Philips","year":"2017","journal-title":"Pharm Stat"},{"key":"R164-20240807","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","article-title":"Group sequential methods in the design and analysis of clinical trials","volume":"64","author":"Pocock","year":"1977","journal-title":"Biometrika"},{"key":"R165-20240807","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"R166-20240807","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMra1510064","article-title":"The primary outcome fails: what next?","volume":"375","author":"Pocock","year":"2016","journal-title":"N Engl J Med"},{"key":"R167-20240807","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMra1601511","article-title":"The primary outcome is positive: is that good enough?","volume":"375","author":"Pocock","year":"2016","journal-title":"N Engl J Med"},{"key":"R168-20240807","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/bimj.200800266","article-title":"Sample size re-estimation in clinical trials","volume":"51","author":"Proschan","year":"2009","journal-title":"Biom J"},{"key":"R169-20240807","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1176\/ajp.156.6.829","article-title":"Placebos, drug effects, and study design: a clinician's guide","volume":"156","author":"Quitkin","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R171-20240807","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1192\/bjp.bp.115.163261","article-title":"Practicing evidence-based medicine in an era of high placebo response: number needed to treat reconsidered","volume":"208","author":"Roose","year":"2016","journal-title":"Br J Psychiatry"},{"key":"R172-20240807","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/biomet\/63.3.581","article-title":"Inference and missing data","volume":"63","author":"Rubin","year":"1976","journal-title":"Biometrika"},{"key":"R174-20240807","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jclinepi.2010.06.008","article-title":"Systematic review reveals heterogeneity in definition of a clinically relevant difference in pain","volume":"64","author":"Ruyssen-Witrand","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R175-20240807","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Ann Intern Med"},{"key":"R177-20240807","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-136-3-200202050-00022","article-title":"The landscape and lexicon of blinding in randomized trials","volume":"136","author":"Schulz","year":"2002","journal-title":"Ann Intern Med"},{"key":"R180-20240807","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1002\/sim.2682","article-title":"Change from baseline and analysis of covariance revisited","volume":"25","author":"Senn","year":"2006","journal-title":"Stat Med"},{"key":"R181-20240807","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/d41586-018-07535-2","article-title":"Statistical pitfalls of personalized medicine","volume":"563","author":"Senn","year":"2018","journal-title":"Nature"},{"key":"R182-20240807","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1002\/sim.3603","article-title":"Measurement in clinical trials: a neglected issue for statisticians?","volume":"28","author":"Senn","year":"2009","journal-title":"Stat Med"},{"key":"R183-20240807","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jpain.2015.03.015","article-title":"Assay sensitivity of pain intensity versus pain relief in acute pain clinical trials: ACTTION systematic review and meta-analysis","volume":"16","author":"Singla","year":"2015","journal-title":"J Pain"},{"key":"R184-20240807","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/j.pain.0000000000000502","article-title":"Pain intensity rating training: results from an exploratory study of the ACTTION PROTECCT system","volume":"157","author":"Smith","year":"2016","journal-title":"PAIN"},{"key":"R185-20240807","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.pain.2012.08.009","article-title":"Adherence to CONSORT harms reporting recommendations in publications of recent analgesic clinical trials: an ACTTION systematic review","volume":"153","author":"Smith","year":"2012","journal-title":"PAIN"},{"key":"R186-20240807","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jpain.2017.02.429","article-title":"The potential role of sensory testing, skin biopsy, and functional brain imaging as biomarkers in chronic pain clinical trials: IMMPACT considerations","volume":"18","author":"Smith","year":"2017","journal-title":"J Pain"},{"key":"R189-20240807","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jpain.2015.01.004","article-title":"Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations","volume":"16","author":"Smith","year":"2015","journal-title":"J Pain"},{"key":"R190-20240807","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jpain.2018.02.016","article-title":"A comparison of the assay sensitivity of average and worst pain intensity in pharmacologic trials: an ACTTION systematic review and meta-analysis","volume":"19","author":"Smith","year":"2018","journal-title":"J Pain"},{"key":"R191-20240807","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.pain.2013.03.003","article-title":"Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations","volume":"154","author":"Smith","year":"2013","journal-title":"PAIN"},{"key":"R193-20240807","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/sim.4780050103","article-title":"A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion","volume":"5","author":"Spiegelhalter","year":"1986","journal-title":"Stat Med"},{"key":"R194-20240807","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1097\/j.pain.0000000000000577","article-title":"Assessment of physical function and participation in chronic pain clinical trials: IMMPACT\/OMERACT recommendations","volume":"157","author":"Taylor","year":"2016","journal-title":"PAIN"},{"key":"R195-20240807","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/annonc\/mdv238","article-title":"Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials","volume":"26","author":"Thall","year":"2015","journal-title":"Ann Oncol"},{"key":"R196-20240807","doi-asserted-by":"crossref","first-page":"e0197844","DOI":"10.1371\/journal.pone.0197844","article-title":"Accurate pain reporting training diminishes the placebo response: results from a randomised, double-blind, crossover trial","volume":"13","author":"Treister","year":"2018","journal-title":"PLoS One"},{"key":"R197-20240807","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jclinepi.2008.08.005","article-title":"Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials","volume":"62","author":"Tsang","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R198-20240807","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.pain.2003.08.001","article-title":"Core outcome domains for chronic pain clinical trials: IMMPACT recommendations","volume":"106","author":"Turk","year":"2003","journal-title":"PAIN"},{"key":"R199-20240807","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.pain.2008.06.025","article-title":"Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations","volume":"139","author":"Turk","year":"2008","journal-title":"PAIN"},{"key":"R200-20240807","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.pain.2007.09.002","article-title":"Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain","volume":"137","author":"Turk","year":"2008","journal-title":"PAIN"},{"key":"R201-20240807","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"N Engl J Med"},{"key":"R208-20240807","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2288-1-6","article-title":"The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study","volume":"1","author":"Vickers","year":"2001","journal-title":"BMC Med Res Methodol"},{"key":"R209-20240807","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1740774518770648","article-title":"The US Food and Drug Administration's expedited approval programs: evidentiary standards, regulatory trade-offs, and potential improvements","volume":"15","author":"Wallach","year":"2018","journal-title":"Clin Trials"},{"key":"R210-20240807","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"key":"R211-20240807","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00031305.2019.1583913","article-title":"Moving to a world beyond \u201cp < 0.05.\u201d","volume":"73","author":"Wasserstein","year":"2019","journal-title":"Am Stat"},{"key":"R212-20240807","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/biomet\/73.3.573","article-title":"On the bias of maximum likelihood estimation following a sequential test","volume":"73","author":"Whitehead","year":"1986","journal-title":"Biometrika"},{"key":"R213-20240807","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"}],"container-title":["PAIN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PR9.0000000000000863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T16:22:54Z","timestamp":1723047774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PR9.0000000000000863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":174,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pr9.0000000000000863","relation":{},"ISSN":["2471-2531"],"issn-type":[{"value":"2471-2531","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"2020-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}